NDAINJECTIONINJECTABLE
Approved
Jul 2011
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
3
Mechanism of Action
protein, Antithrombin III, to induce a conformational change, which markedly enhances the serine protease activity of Antithrombin III, thereby inhibiting the activated coagulation factors involved in the clotting sequence, particularly Xa and IIa. Small amounts of heparin inhibit Factor Xa, and…
Clinical Trials (3)
Study With Heparin Sodium in Subcutaneous Administration
Started Aug 2022
Study With Heparin Sodium in Intravenous Administration
Started Feb 2021
Full Dose Tenecteplase (TNK-tPA) Together With Heparin Sodium, Full Dose Tenecteplase With Enoxaparin, Half Dose Tenecteplase Together With Abciximab and Heparin Sodium in Patients With Acute Myocardial Infarction (AMI)
Started May 2000
5,989 enrolled
Myocardial Infarction